Pharmadax Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 303.91 million compared to TWD 397.15 million a year ago. Net loss was TWD 386.13 million compared to TWD 310.51 million a year ago.

Basic loss per share from continuing operations was TWD 5.44 compared to TWD 4.49 a year ago. Diluted loss per share from continuing operations was TWD 5.44 compared to TWD 4.49 a year ago.